Skip to main content
Evidence Snapshot

T-cell

CHEMBL614309 CELL-LINE
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:00Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614309
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats T-cell as ChEMBL target CHEMBL614309. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
T-cell
CELL-LINE
As of 2026-09-13
ChEMBL target ID
CHEMBL614309
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why T-cell matters

As of 2026-09-13

T-cell is reviewed as T-cell; the current evidence base includes 13 approved drugs, 1449 compounds, and 397 assays, with lead potency reaching pChEMBL 10.3.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 13 approved drugs, 1449 compounds, and 397 assays for this target. The dominant activity type is IC50. CHEMBL846 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL846 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
13 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why T-cell matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1449
Total Compounds
397
Total Assays
13
Approved Drugs
IC50: 1067.0, EC50: 116.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL846
 10.3 IC50 Approved
No preferred name
CHEMBL212689
 9.9 IC50 —
No preferred name
CHEMBL412818
 9.7 IC50 —
No preferred name
CHEMBL269732
 9.7 IC50 Approved
No preferred name
CHEMBL266443
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
POMALIDOMIDE
CHEMBL43452
 2013
TOFACITINIB
CHEMBL221959
 2012
DASATINIB
CHEMBL5416410
 2006
LENALIDOMIDE
CHEMBL848
 2005
MYCOPHENOLIC ACID
CHEMBL866
 2004
SIROLIMUS
CHEMBL413
 1999
TACROLIMUS ANHYDROUS
CHEMBL269732
 1994
CYCLOSPORINE
CHEMBL160
 1983
CALCITRIOL
CHEMBL846
 1978
DEXAMETHASONE
CHEMBL384467
 1958
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:00Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614309